Dersimelagon (MT-7117)

Erythropoietic protoporphyria or X-linked protoporphyria

Manufacturer: LEO Pharma
Regulatory submission: NDA submitted June 2026
Launch: Potential launch in 2027
Last updated: September 21, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

21 evidence topics · 14 sources

Sunlight avoidance and photoprotective measures3 evidence topics · 3 sources
Melanocortin 1 receptor agonists7 evidence topics · 8 sources
Oral antioxidants and other systemic agents2 evidence topics · 5 sources
Phototherapy and sunlight hardening1 evidence topic · 1 source
Management of acute phototoxic reactions1 evidence topic · 1 source
Management of hepatobiliary complications3 evidence topics · 2 sources
Limitations of current therapies4 evidence topics · 7 sources